Glaucoma News

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended marketing authorization approval for Rhokiinsa for the reduction of IOP in primary open-angle glaucoma or ocular hypertension, Aerie Pharmaceuticals announced in a press release.

LAS VEGAS – Evaluating the pupil is an often-neglected procedure, according to Mario Gutierrez, OD, here at Vision Expo West.

Aerie Pharmaceuticals has submitted a prior approval supplement to the FDA to allow Rocklatan production in its Athlone, Ireland, facility, according to a press release.

LAS VEGAS – Justin Schweitzer, OD, said here at Vision Expo West that the increase in the number of glaucoma patients necessitates optometrists’ involvement in both long- and short-term postoperative management. ODs must monitor patients who underwent minimally invasive glaucoma surgery for hyphema, hypotony and IOP spikes. In addition, glaucoma medications should be removed one at a time, after 1 week, once target pressure is met.

PARIS — In patients with uncontrolled open-angle glaucoma, better reduction of IOP was achieved when ab interno trabeculotomy was added to the combined treatment of phacoemulsification plus endocyclophotocoagulation than when it was not added, according to a study.

Glaucoma impacts patients and care givers significantly, according to a national survey conducted by the Glaucoma Research Foundation and supported by Aerie Pharmaceuticals.

PARIS — The HORIZON trial at 3 years demonstrated that the Hydrus Schlemm’s canal stent added sustained IOP lowering to that achieved by cataract surgery alone, Gus Gazzard, MD, MBBChir, FRCOphth, said at the European Society of Cataract and Refractive Surgeons meeting.

Here are some of the past week’s top stories on Healio.com/OSN:

iSTAR Medical has completed 40 million euros in Series C financing to be used in the development of its MINIject device for the treatment of glaucoma, according to a press release.

COEUR D’ALENE, Idaho — Glaucoma was strongly associated with higher failure rates after Descemet’s stripping automated endothelial keratoplasty, according to a poster presented at the Women in Ophthalmology Summer Symposium.